The company recently reported results for H1 FY21, featuring a 46% y-o-y increase in Cxbladder sales to NZ$3.3m. The US business grew 46% to NZ$2.9m and was assisted by the inclusion of Cxbladder into a local coverage determination (LCD) enabling reimbursement at US$760 per test from the US Centers for Medicare and Medicaid Services (CMS) on all tests after 1 July (corresponding to the second half of H1 FY21). The outlook for growth in the US business is strong due to the change in reimbursement ....
25 Jan 2021
Pacific Edge - Operating revenue up 46% on strong US growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pacific Edge - Operating revenue up 46% on strong US growth
Pacific Edge Limited (PEB:NZE) | 0 0 0.0% | Mkt Cap: 186.5m
- Published:
25 Jan 2021 -
Author:
Maxim Jacobs -
Pages:
6
The company recently reported results for H1 FY21, featuring a 46% y-o-y increase in Cxbladder sales to NZ$3.3m. The US business grew 46% to NZ$2.9m and was assisted by the inclusion of Cxbladder into a local coverage determination (LCD) enabling reimbursement at US$760 per test from the US Centers for Medicare and Medicaid Services (CMS) on all tests after 1 July (corresponding to the second half of H1 FY21). The outlook for growth in the US business is strong due to the change in reimbursement ....